Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development.

Abstract

Thyroid cancer is the most prevalent endocrine malignancy and the reported incidence of thyroid cancer has continued to increase in recent years. Since 2019, coronavirus disease 2019 (COVID-19) has been spreading worldwide in a global pandemic. COVID-19 aggravates primary illnesses and affects disease management; relevant changes include delayed diagnosis and treatment. The thyroid is an endocrine organ that is susceptible to autoimmune attack; thus, thyroid cancer after COVID-19 has gradually attracted attention. Whether COVID-19 affects the diagnosis and treatment of thyroid cancer has also attracted the attention of many researchers. This review examines the literature regarding the influence of COVID-19 on the pathogenesis, diagnosis, and treatment of thyroid cancer; it also focuses on drug therapies to promote research into strategies for improving therapy and management in thyroid cancer patients with COVID-19.

• Authors: Na Qu, Zongguang Hui, Zhixin Shen, Chengxia Kan, Ningning Hou, Xiaodong Sun, Fang Han
• Journal: Frontiers in endocrinology (Front Endocrinol (Lausanne)) Vol. 13 Pg. 873027 ( 2022) ISSN: 1664-2392 [Print] Switzerland
• PMID: 35600591 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2022 Qu, Hui, Shen, Kan, Hou, Sun and Han.

Topics

• Drug Development
• Humans
• Pandemics
• SARS-CoV-2
• Thyroid Neoplasms (drug therapy, epidemiology)
• COVID-19 Drug Treatment